Výsledky vyhledávání - "C. Mallinckrodt"

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab

Publikováno v: Mallinckrodt, C, Tian, Y, Aisen, P S, Barkhof, F, Cohen, S, Dent, G, Hansson, O, Harrison, K, Iwatsubo, T, Mummery, C J, Muralidharan, K K, Nestorov, I, Nisenbaum, L, Rajagovindan, R, von Hehn, C, van Dyck, C H, Vellas, B, Wu, S, Zhu, Y, Sandrock, A, Chen, T & Budd Haeberlein, S 2023, ' Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab ', Journal of Prevention of Alzheimer's Disease, vol. 10, no. 2, pp. 171-177 . https://doi.org/10.14283/jpad.2023.6
Journal of Prevention of Alzheimer's Disease, 10(2), 171-177. Springer International Publishing AG

Objectives: Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer’s disease (AD) have been published. In EMERGE, but not in ENGAGE, high-dose aducanumab demonstrated sign

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd07dbe73e27c792379e4f551475c168
https://research.vumc.nl/en/publications/18353bb7-a328-4866-843c-42c58403e679

Zobrazit plný text záznamu

‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings

Autor: S.P. Dickson, A.M. Wessels, S.A. Dowsett, C. Mallinckrodt, J.D. Sparks, S. Chatterjee, S. Hendrix

Publikováno v: The Journal Of Prevention of Alzheimer's Disease.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::85fce03734a032c8fe77103a405d3c74
https://doi.org/10.14283/jpad.2023.50

Zobrazit plný text záznamu

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

Publikováno v: Journal of Prevention of Alzheimer's Disease, 9(2), 197-210. Springer International Publishing AG
Budd Haeberlein, S, Aisen, P S, Barkhof, F, Chalkias, S, Chen, T, Cohen, S, Dent, G, Hansson, O, Harrison, K, von Hehn, C, Iwatsubo, T, Mallinckrodt, C, Mummery, C J, Muralidharan, K K, Nestorov, I, Nisenbaum, L, Rajagovindan, R, Skordos, L, Tian, Y, van Dyck, C H, Vellas, B, Wu, S, Zhu, Y & Sandrock, A 2022, ' Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease ', Journal of Prevention of Alzheimer's Disease, vol. 9, no. 2, pp. 197-210 . https://doi.org/10.14283/jpad.2022.30

Background: Alzheimer’s disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in pathogenesis. Aducanumab is a human monoclonal antibody directed against aggregated soluble an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25356f937683da76b27d9eec33c332a0
https://research.vumc.nl/en/publications/104cb695-ffcb-4502-aba8-9ab998dcbd40

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

Autor: Melinda Gooderham, Kim Papp, Paula Polzer, Andrew Blauvelt, L. Zhang, Noah Agada, Richard G. Langley, Peter Foley, C Mallinckrodt

Publikováno v: The British journal of dermatology. 178(6)

Background Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter. Objective To

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a8292dc3c728f47ab863c09ed842f3e
https://pubmed.ncbi.nlm.nih.gov/29897126

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The effects of hyperoxia on the biosynthesis of cyclooxygenase products and haemodynamic response to nitric oxide synthase inhibition with L-NAME in endotoxaemic pigs

Autor: James S. Gaynor, Khursheed R. Mama, Peter W. Hellyer, Bonnie D Wright, Ann E. Wagner, C Mallinckrodt

Publikováno v: Journal of Veterinary Pharmacology and Therapeutics. 21:348-357

The interaction between constitutive nitric oxide and oxygen may depend on the degree of tissue oxygenation and may play a critical role in the pathophysiological response to endotoxaemia. We investigated if hyperoxia (100% O2) attenuated the systemi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e3d2a12ed50a2ee59afe534cbd84559
https://doi.org/10.1046/j.1365-2885.1998.00147.x

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PerForM, a High Channel-Count, Modular Downhole System for Permanent Reservoir Monitoring

Autor: J. Buss, J.B.U. Haldorsen, T. Hilton, C. Mallinckrodt

Publikováno v: Abstracts.

We have developed a cost-effective downhole PRM system. This system can be installed on production tubing and has a flexible interface, which allows integrating data from other sensors. The system uses electric geophones with electric (copper) commun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::166d1afaff5901936b5af4f6418178ab
https://doi.org/10.3997/2214-4609.20131313

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání